Safety and Efficacy of an Oral Inhibitor of the Purinergic Receptor P2X7 in Adult Patients with Moderately to Severely Active Crohn's Disease: A Randomized Placebo-controlled, Double-blind, Phase IIa Study

Alexander Eser, Jean Frederic Colombel, Paul Rutgeerts, Severine Vermeire, Harald Vogelsang, Martin Braddock, Tore Persson, Walter Reinisch

Research output: Contribution to journalArticlepeer-review

128 Scopus citations

Abstract

Background: AZD9056 is a selective orally active inhibitor of the purinergic receptor P2X 7, which is a key player in the generation and secretion of several proinflammatory cytokines involved in the pathogenesis of Crohn's disease (CD). The aim of this phase IIa study was to assess the efficacy and safety of AZD9056 for the treatment of moderately to severely active CD. Methods: We conducted a placebo-controlled, multicenter, double-blind phase IIa study in patients with moderately to severely active CD as defined by a CD Activity Index (CDAI) of at least 220. Patients were randomized in a 2:1 mode either to 200 mg of AZD9056 administered orally as a tablet once daily for 28 days or matching placebo. Primary endpoint was the change in CDAI from baseline at day 28, and secondary endpoints included clinical remission (CDAI < 150) and CDAI 70 response and improvement in the quality of life measures Short Form 36 and Inflammatory Bowel Disease Questionnaire. Changes in serum C-reactive protein and fecal calprotectin were assessed. Results: In total, 34 patients were enrolled, 24 to AZD9056 and 10 to placebo. The CDAI dropped in AZD9056-treated subjects from a baseline mean of 311 to 242 and from 262 to 239 in placebo-treated subjects (P 0.049). Remission and response rates were numerically higher with AZD9056 versus placebo, (n =5.24% versus n =1.11%, P= 0.43 and n= 11.52% versus n= 2.22%, P= 0.13, respectively). Marked decrease in disease activity was observed for the CDAI subcomponents, pain and general well-being. Apart from a statistically significant improvement in the Mental Component Score of Short Form 36 for AZD9056 versus placebo (P= 0.017), no other differences in measurements of quality of life could be observed. There was no decrease in concentrations of serum C-reactive protein and fecal calprotectin during treatment. AZD9056 was well-tolerated, and no serious adverse events were reported. Conclusions: Our data suggest that the purinergic receptor P2X 7 antagonist AZD9056 has the potential to improve symptoms in patients with moderate-to-severe CD combined with a beneficial risk profile. Although the lack in change of inflammatory biomarkers questions its anti-inflammatory potential, the results obtained in this study rather suggest P2X 7 antagonism for the treatment of chronic abdominal pain.

Original languageEnglish
Pages (from-to)2247-2253
Number of pages7
JournalInflammatory Bowel Diseases
Volume21
Issue number10
DOIs
StatePublished - 20 Jul 2015

Keywords

  • Crohn's disease
  • abdominal pain
  • inflammatory bowel disease
  • oral P2X7 inhibitor
  • randomized controlled trial

Fingerprint

Dive into the research topics of 'Safety and Efficacy of an Oral Inhibitor of the Purinergic Receptor P2X7 in Adult Patients with Moderately to Severely Active Crohn's Disease: A Randomized Placebo-controlled, Double-blind, Phase IIa Study'. Together they form a unique fingerprint.

Cite this